Biodesix to present new cancer survival data at ASCO 2025, highlighting the impact of the VeriStrat test in treatment decisions.
Quiver AI Summary
Biodesix, Inc. announced that it will present new data at the 2025 American Society of Clinical Oncology Annual Meeting regarding the use of its VeriStrat test to predict survival outcomes in patients with PD-L1 ≥50% metastatic non-small cell lung cancer (NSCLC) undergoing chemoimmunotherapy. The study, featuring over 5,000 patients, reveals significant findings, particularly showing that those with a "VeriStrat Poor" result have over three times higher two-year survival rates when treated with a combination of immunotherapy and chemotherapy compared to immunotherapy alone. The test categorizes patients’ immune responses as either "Hot" or "Cold," aiding oncologists in treatment decision-making. Biodesix’s ongoing research also suggests potential applications of the VeriStrat test for other solid tumors, with results expected later in 2025.
Potential Positives
- Significant presentation of new data at the prestigious 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, demonstrating Biodesix's ongoing commitment to advancing cancer treatment.
- New findings highlight the effectiveness of the VeriStrat test in predicting improved overall survival for patients with non-small cell lung cancer when using a combined immunotherapy and chemotherapy approach.
- The data supports potential decision-making improvements for oncologists, enhancing personalized treatment strategies for lung cancer patients, which could lead to better patient outcomes.
- Indication that the VeriStrat test may extend its applicability to other solid tumors, suggesting future growth opportunities for Biodesix's diagnostic solutions.
Potential Negatives
- The mention of adverse reactions to immunotherapy treatments raises concerns about the potential risks associated with their products.
- The reliance on the VeriStrat test for treatment decision-making suggests that not all patients may benefit from available therapies, which could indicate limitations in their diagnostic capabilities.
- The upcoming data release from a different ongoing study may imply that current results are preliminary and not yet fully validated, potentially affecting the credibility of the findings presented.
FAQ
What is the focus of Biodesix's presentation at ASCO 2025?
Biodesix will present data on using a host immune classifier to predict survival in metastatic non-small cell lung cancer (NSCLC) patients.
Who will present the data at the ASCO Annual Meeting?
The data will be presented by Dr. Vamsidhar Velcheti, MD, from NYU Langone’s Perlmutter Cancer Center.
What is the VeriStrat test used for?
The VeriStrat test measures a patient's immune response to lung cancer, classifying results as either Hot (Good) or Cold (Poor).
What did the new data reveal about treatment outcomes?
The data showed significant overall survival improvement for patients with VeriStrat Poor results receiving immunotherapy plus chemotherapy.
Are there ongoing studies related to the VeriStrat test?
Yes, there are preliminary results from another study suggesting the VeriStrat test may have applications in other solid tumors.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BDSX Insider Trading Activity
$BDSX insiders have traded $BDSX stock on the open market 19 times in the past 6 months. Of those trades, 4 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $BDSX stock by insiders over the last 6 months:
- JACK W SCHULER has made 3 purchases buying 4,823,239 shares for an estimated $1,439,464 and 0 sales.
- SCOTT HUTTON (President & CEO) has made 0 purchases and 3 sales selling 87,435 shares for an estimated $78,663.
- LAWRENCE T. JR KENNEDY purchased 35,000 shares for an estimated $40,561
- ROBIN HARPER COWIE (CFO, Sec'y & Treasurer) has made 0 purchases and 3 sales selling 25,656 shares for an estimated $23,147.
- KIERAN O'KANE (Chief Commercial Officer) has made 0 purchases and 3 sales selling 18,004 shares for an estimated $16,368.
- GARY ANTHONY PESTANO (Chief Development Officer) has made 0 purchases and 3 sales selling 17,193 shares for an estimated $15,636.
- CHRIS VAZQUEZ (Chief Accounting Officer) has made 0 purchases and 3 sales selling 3,854 shares for an estimated $3,434.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BDSX Hedge Fund Activity
We have seen 24 institutional investors add shares of $BDSX stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SIO CAPITAL MANAGEMENT, LLC removed 4,338,514 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,637,926
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 4,038,065 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $6,178,239
- FARALLON CAPITAL MANAGEMENT LLC removed 1,952,118 shares (-51.2%) from their portfolio in Q1 2025, for an estimated $1,220,464
- AIGH CAPITAL MANAGEMENT LLC removed 1,907,221 shares (-30.9%) from their portfolio in Q1 2025, for an estimated $1,192,394
- ESSEX INVESTMENT MANAGEMENT CO LLC removed 971,197 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $1,485,931
- AMH EQUITY LTD removed 604,095 shares (-92.7%) from their portfolio in Q1 2025, for an estimated $377,680
- MONASHEE INVESTMENT MANAGEMENT LLC added 549,121 shares (+15.7%) to their portfolio in Q1 2025, for an estimated $343,310
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BDSX Analyst Ratings
Wall Street analysts have issued reports on $BDSX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 05/14/2025
- Canaccord Genuity issued a "Buy" rating on 05/14/2025
To track analyst ratings and price targets for $BDSX, check out Quiver Quantitative's $BDSX forecast page.
Full Release
LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The presentation titled “ Host immune classifier to predict survival with chemoimmunotherapy in PD-L1 ≥50% metastatic NSCLC ” features data from the INSIGHT study (NCT03289780) which enrolled greater than 5,000 patients with non-small cell lung cancer (NSCLC). The data will be presented by Dr. Vamsidhar Velcheti, MD, Director of Thoracic Oncology at NYU Langone’s Perlmutter Cancer Center.
The VeriStrat test measures a patient’s immune response to lung cancer and is reported as either Host Immune Classifier Hot ( VeriStrat Good ) or Host Immune Classifier Cold ( VeriStrat Poor ). The new data strengthens prior findings and demonstrates statistically significant improvement of overall survival (OS) in patients with a VeriStrat Poor result when receiving immunotherapy combined with chemotherapy versus immunotherapy as a single agent. Notably, the two-year survival rate was more than three times higher in patients receiving immunotherapy plus chemotherapy compared to those who received immunotherapy alone. Additionally, patients with a VeriStrat Good result had comparable survival when receiving either treatment regimen.
“Immunotherapy treatments represent one of the most important recent innovations in lung cancer treatment, unfortunately some patients do not respond to these treatments while others may experience adverse reactions,” said Gary Pestano, Ph.D., Chief Development Officer, Biodesix. “This new data suggests that the VeriStrat test has the potential to help oncologists evaluate the benefits and risks of certain treatments for specific patients. The VeriStrat test may then be an aid in decision-making on whether to escalate or de-escalate treatment and improve patient outcomes.”
Preliminary results from a different ongoing study suggest that the VeriStrat test may have similar indications in patients with other types of solid tumors. Data from this study is expected to be published later in 2025.
About Biodesix
Biodesix is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, marketed as Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics. For more information, visit biodesix.com .
Trademarks: Biodesix, Biodesix Logo, Nodify Lung, and IQLung are trademarks or registered trademarks of Biodesix, Inc.
Contacts:
Media:
Natalie St. Denis, Director Corporate Communications, Biodesix
[email protected]
(720) 925-9285
Investors:
Chris Brinzey, Partner, ICR Healthcare
[email protected]
(339) 970-2843
